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• Breast cancer is the most common type of cancer in 
females
• treatment is complex and relies on several factors
• For early-stage breast cancer usually surgery
• For more aggressive tumors chemotherapy or 
hormonal therapy before surgery
• After surgery        to lower the risk of recurrence
adjuvant therapies include radiation therapy, 













• In recent years, the presence of breast cancer tumor markers has been investigated
• estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 
receptor 2 (HER2)
• HER2 overexpression malignant progression and cancer
• HER2 overexpression in approximately 25% of all breast cancers more 
aggressive disease and endocrine therapy resistance
• an appealing in targeted therapy
HER2
low levels in the 
epithelial cells
lungs bladder breast pancreas prostate
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• One of the significant advancements in breast cancer 
treatment mAb-based therapies
• The humanized monoclonal antibody Trastuzumab
(TRA), sold under the brand name Herceptin among 
others, was FDA approved in 1998 for the treatment of 
HER2-positive breast cancers
• TRA enhance the effects of chemotherapy 













• TRA a humanized IgG(1) kappa monoclonal antibody 
• 145.5 kDa
• high and specific affinity towards HER2 receptors
• stop tumor development cell signaling 
• reduced PI3K/Akt signaling
• enhanced degradation of HER2 receptors
• antibody-dependent cellular cytotoxicity (ADCC) 
10
• TRA         is currently used as a first-line treatment of breast cancer
• However, drug resistance is inevitable
• alternative treatment options Anti-HER2 immunoliposomes
combine the tumor-targeting properties of mAbs, with the drug 
delivery properties 
• offering prolonged inhibition of the HER2 pathway
• reducing drug side effects
• increasing blood circulation time
• increasing drug concentrations at target sites
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• Liposomes are one of the most widely used nanocarriers in drug delivery
• nanosized to microsized
• spheres of phospholipid bilayers separated by aqueous compartments
• the circulation-time of liposomes can be increased and their detection by the 
reticuloendothelial system (RES) reduced by conjugating stealth-imparting 
polymers to their surfaces
• The most widely used polymeric substance poly-ethylene glycol (PEG)
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• Antibody therapeutics have revolutionized the treatment of cancer over the past 
few decades
• Antibodies in targeted therapy to deliver potent chemotherapeutic agents in 
the form of antibody–drug conjugates (ADCs) or as targeting ligands decorating 
the surfaces of nanocarriers
• Immunoliposomes provide a complementary and more advantageous, drug 
delivery strategy to ADCs
• The large size of ADCs often hinders their diffusion into the intratumoral space
• immunoliposomes higher drug-carrying capacity (20,000–150,000 drug 
molecules/liposome) compared to ADCs 
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• SDDSs in their target sites release their contents when exposed to either an 
internal or external stimulus
• the trigger in this work ultrasound (US)
• US a cyclic sinusoidal acoustic wave 
• frequencies higher than those of the human hearing range (> 20 kHz)
• the biological effects of US can be either :
• thermal are caused by energy dissipation
• Mechanical occur because of the acoustic wave propagation and pressure 
variations
• The mechanical effects of US  form gas bubbles due to changes in pressure
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• In this study:
• calcein and Doxorubicin (DOX)
• loaded pegylated liposomes 
• with TRA
• to target breast cancer cells
• LFUS applied to trigger the release of calcein and DOX 
from the liposomes




Preparation of control liposomes
• using the thin-film hydration method
cholesterol, DPPC, and 
DSPE-PEG(2000)-NH2 
at molar ratios of 30:65:5   
4 ml chloroform 
evaporated 50 ℃ for 15 min 
hydrated 2 ml of a 
30-mM calcein
solution pH=7.4 To obtain unilamellar vesicles









• same protocol liposomes encapsulating ammonium sulfate 
• The ammonium sulfate method was used to load DOX into the formed liposomes
centrifuging through a 
Sephadex G-25 gel filtration 
column




DOX was added (DOX to 
lipid ratio of 1:6 (w/w))
Liposomes were purified with a Sephadex G-25 gel filtration 
column (previously equilibrated with HEPES buffer) 
0.11-M solution of 
ammonium sulfate pH=5.5  
to hydrate the dry lipid film
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Preparation of Trastuzumab (TRA)-liposomes
excess TRA and any free 
drugs were purified in a 
Sephacryl S-200 h column 
Calcein and DOX 
liposomes were prepared 
cyanuric chloride was dissolved in 
acetone 10 mg/ml solution
9.23 μl was diluted in 0.5 ml 
deionized water
was added to 1 ml of the 
liposomal formulations
stir for 3 h
pH=8.5 0℃ substitution of the chloride particle 
on the cyanuric chloride with the 
proton of the NH2 group of the 
liposomes
• the linking of the N-
terminus on the amino 
acids of TRA to 
cyanuric chloride
1 mg TRA in 0.5 ml 
borate buffer
was added to the 
liposomes
stirring overnight
stored at 4 ℃
pH 8.5
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Particle size and polydispersity evaluation
• particle size 
• polydispersity index(PDI)
• 25 °C
• using DynaPro NanoStar
DynaPro NanoStar Dynamic Light Scattering
20
Liposomes characterization Result 1
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Estimation of phospholipid content
• using the Stewart Assay
using UV–Vis spectroscopy at 
Amax = 485 nm against 
chloroform as a blank
liposome samples were 
dried under vacuum 
dissolved in chloroform
was sonicated to 
break the liposomes 
solution was added to 2 ml of 
ammonium ferrothiocyanate
centrifugation step resulted in 
a biphasic system
the top dark layer was discarded
the bottom clear chloroform layer its 
optical density measured 
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Trastuzumab conjugation to the liposomes
• Bicinchoninic Acid Assay (BCA)
BCA reagent was prepared : mixing 
QuantiPro QA buffer, QuantiPro QB, 
and CuSO4 in a ratio of 25:25:1
1mL of the reagent was added to 1 
ml of PBS and 100 μl of the 
liposomal solution incubation
60℃ 
The optical density 
562 nm1 h
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Figure 1. Protein concentrations (per mg of lipids) for the control and TRA-liposomes




A 2D map was created by keeping the 
hydrophone at a constant depth 
ultrasonic probe produced 
LFUS (at 20 kHz)
power amplitude: 20%, 25% and 30%
Measuring the power 
densities: hydrophone
• the waves produced by the US create a 
pressure variation 
• be detected by hydrophone and 
converted into voltage signals
The signals are fed to a digital 
storage oscilloscope
analyzed  MATLAB software
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• The value of the hydrophone voltage sensitivity was provided/reported by the 
hydrophone manufacturer as 30 μV/Pa
• the ultrasound power density ‘I’, in Watt/cm2, is given by the  equation:
• ‘Z’ is the acoustic impedance of the medium (the impedance of water= 1.48 × 106 ) 
• ‘P’ is the pressure measured in Pascals
• The measured voltage signals were converted into acoustic pressure in Pascal using 
the equation:
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Determination of the different power densities of the LFUS
• Power densities values measured with the hydrophone




Low-Frequency ultrasound release studies 
• The release of calcein and DOX from liposomes was triggered  20-kHz low-frequency ultrasonic probe 
excitation emission
Calcein 495 nm 515 nm 
DOX ⁓485 nm 595 nm
monitored by fluorescence 
changes using a 
Spectrofluorometer
75 μL of liposomes in 3 mL of 
PBS in a fluorescence cuvette
The initial fluorescence 
intensity I0 was measured for 
60 s before sonication
US with 20 s on and 10 s off for 
calcein liposomes 20 s on, 20 s off for 
DOX-liposomes
to account for the thermal effects of US
three different power densities, 6.2, 9 and 
10 mW/cm2
The pulsed US cycles were continued 
until a fluorescence plateau 
50 μL of Triton X-100 were 
added to lyse the liposomes 
(simulating 100% drug release)
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• I0 the baseline intensity
• It the intensity at time
• I∞ the highest fluorescence intensity value obtained
• The percent of drug released from the liposomes Cumulative Fraction Release (CFR)
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Figure 2. Normalized release profiles of the control and TRA-liposomes
loaded with calcein at 6.2 mW/cm2, 9 mW/cm2 and 10 mW/cm2
 Result 4
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Low-frequency ultrasound (LFUS) triggered release
• TRA-liposomes were more acoustically sensitive releasing around 92%
• the control liposomes 86% released 
• the presence of the TRA molecules slightly destabilize the membrane 
making the liposomes more susceptible to acoustic mechanical waves
 Result 4
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• the mechanical index (MI) parameter to indicate the possibility of the occurrence of cavitation
• The negative pressure is dependent:
• the acoustic impedance of water, Z, (1.48 MPa sec/m )
• the intensity of the LFUS, I, 
• The threshold of 




collapse cavitation MI = 0.3
biological effects MI > 0.7




SKBR3 (HER2 + cells)             DMEM
MDA-MB-231 (HER2- cells)             RPMI
• 10% FBS
• 1% penstrep
• 37 °C 
• 5% CO2
incubation
1 × 104 cells per well 
96-well plates 
24 h 
different treatments:8 μM per well 
(n=3)
• free DOX
• DOX-loaded control liposomes 
• DOX-TRA liposomes
• Drug-free control liposomes as 
neg control
were incubated 4 h
LFUS for 5 min in a 35-kHz bath
One plate of each cell line was 





microplate reader at 570 nm
medium was replaced with the MTT medium
37 °C
4 h
100 μl of DMSO 
15 min
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In vitro cytotoxicity analysis
• liposomes without DOX encapsulation were used as control cell viability (~ 100%)
• cytotoxicity is due to the action of DOX and not the liposomes themselves
• the toxicity of LFUS (35 kHz) on the cells was also examined





1. synergistic effects of using LFUS to trigger drug release 
2. sonoporation effect    enhancing the cytotoxic performance of the free drug
%viability
SKBR3 MDA-MB-231
TRA-liposomes 38.9 ± 2.54% 58.0 ± 1.91%
control liposomes 53.1 ± 3.89% 51.1 ± 0.933%
LFUS+TRA-liposomes1 27.4 ± 0.260% 40.1 ± 0.216% 
LFUS+control liposomes1 32.9 ± 1.31% 38.7 ± 0.858%
DOX+LFUS2 14.8 ± 2.52% Not reported




the flow cytometer analysis
SKBR3 and MDA-MB-231 cells 
(2×105 cells/ml) in 6-well plates 
24 h
treat with the control and 
TRA-DOX liposomes 
4 h
• LFUS bath 35-kHz    5 min 
• power density 20 mW/cm2
• One plate from each cell line 
was treated with both types of 
liposomes without LFUS as a 
reference
1 h Trypsin was added to detach the cells resuspended in PBS 
38
Flow cytometry analysis of cellular uptake of calcein
• HER2 + (SKBR3) and HER2- (MDA-MB-231) cells 
• incubated with either the control or TRA-liposomes for 4 h
• the average calcein fluorescence intensity in SKBR3 cells 
• TRA-liposomes (25,160) 
• control liposomes (7236)
• Sonicating the cells with LFUS (35-kHz) for 5 min 
• further increase in calcein fluorescent intensity with TRA-liposomes (32,735)




• The recorded increase in the fluorescence intensity of calcein inside SKBR3 cells when 
incubated with TRAliposomes compared to control liposomes  due to the overexpressed 
HER2 receptors
• same experiment a triple-negative cell line (MDA-MB-231)
• no significant difference inside MDA-MB-231 cells with the control(10,022) or TRA-
liposomes(13,914)
• low expression of HER2 receptors on the surface of MDA-MB-231 cells    reducing 
the targeting ability of the TRA-liposomes              low cellular uptake of the calcein
 Result 7
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• Flow cytometry analysis of calcein uptake following their incubation with control liposomes or TRA-liposomes
followed by ultrasound (US) sonication (35-kHz) for 5 min at a power density of 20 mW/cm2





• The suggested mechanism of the binding of immunoliposomes to HER2 receptors 
overexpressed on the surface of SKB3 cells was examined
• blocking HER2 receptors to prevent the targeted liposomes from binding 
• SKBR3 cells incubated first with free Trastuzumab (1 mg/ml) for 30 min 
• incubated for 4 h with the different liposomal formulations
• no significant difference with the control liposomes in the presence or absence of free TRA 
(p-value = 0.095)
• for TRA-liposomes, calcein uptake was significantly hindered when HER2 receptors were 
first blocked with free TRA (p-value = 3.23 × 10-5)
 Result 8
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• Flow cytometry analysis showing calcein fluorescence intensity inside SKBR3 cells incubated with the 




fluorescent microscope excitation filter at 
470–495 nm and emissions at 510–550 nm
SKBR3 cells (2×105 cells/ml) 
two 6-well plates
incubation with either 
control or TRA-liposomes 
One of the two plates was 
sonicated (35 kHz) 5 min
The media was removed 
were washed with PBS 
fixed with 4% Formaldehyde washing PBS buffer 
24 h 4 h
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Fluorescence microscopy images of SKBR3 cells 
following 4 h incubation with 
• control liposomes
• TRA liposomes encapsulating calcein






• Results were reported as average ― standard deviation (SD)





• Targeted drug delivery is a promising technique in cancer treatment 
• Liposomes are among the most successful nanocarriers
1. their high biodegradability
2. biocompatibility
3. ability to encapsulate both hydrophilic and hydrophobic drugs
• Antibodies are an attractive choice as targeting molecules conjugated to liposomes (immunoliposomes) to 
target certain receptors, such as HER2 receptors, overexpressed on the surface of breast cancer cells
• In this study  conjugating a monoclonal antibody (trastuzumab) to pegylated liposomes and triggered 
with low-frequency ultrasound (LFUS) to enhance the release of the encapsulated drug 
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Immunoliposomes:
• enhance the efficiency
• reduce the off-target toxicity of the antineoplastic agent
• higher and more toxic concentration of one or more drugs to be delivered to the cells
• deliver large molecules such as genes
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• Liposome-encapsulated doxorubicin was developed to reduce the toxicity while enhancing the 
targeting efficiency of DOX
• polyethylene glycol (PEG)  creates a hydrophilic shield that protects the liposomes from 
elimination and ensures a prolonged circulation time in the body
• Liposomal DOX has been studied widely over the past several years. Some liposomal formulations 
of DOX   extensively evaluated for their safety and efficacy
• less cardiotoxicity and gastrointestinal toxicity 
• Doxil (used in the US since 1995) 
• Myocet (community authorization by the European Commission since 2000)
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• Our synthesized immunoliposomes (TRA-liposomes) were within the recommended size (< 200 nm) 
to benefit from EPR effect
• LFUS (at 20 kHz) triggered calcein release from the liposomes 
• the release increased with the increase in the US power density
• Previous studies LFUS can trigger drug release from the liposomes in a controlled manner
• LFUS can produce both thermal and mechanical effects
• both may contribute to enhancing drug release from the liposomes
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• When US was applied in our experiments, both types of liposomes released most of 
their content  ≤ 31 °C
• lower than the transition temperature of DPPC (41.3 °C)
• the mechanical effects in the form of cavitation are the likely driving forces behind 
drug release
• according to the calculated MI values (below the threshold required for the collapse 
cavitation (MI = 0.3)) stable cavitation
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• Cavitation may cause “sonoporation” 
• which is the ability of US to modify cellular membranes’ permeability by creating 
transient pores in the membrane
• previous studies   cavitation-induced drug release from sonicated liposomes 
occured through pore formation rather than the destruction of the whole membrane
• LFUS application was not toxic to the cells 
• confirms that sonoporation has no adverse effect on cell viability for the power density 
and frequency used in this study
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• when the control liposomes were incubated with SKBR3 cells liposomes can transfer their 
load to the cytoplasm by fusing with the cellular membrane
• Vogel et al   this process is slow and increases gradually with time
• TRA-liposomes deliver their cargo to cells 
• by membrane fusion 
• by receptor-mediated endocytosis
• allow the cellular uptake of a larger number of liposomes in a shorter
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• LFUS exposure has a visible effect on the action and uptake of free DOX due to the sonoporation effect
• the combination of immunoliposomes and US a promising targeted technique to treat HER2 + 
primary or secondary breast cancer cell lines
• This can be achieved by: 
• injecting the patients with immunoliposomes encapsulating the drug
• a clinically approved ultrasonic probe focuses acoustic waves on the tumor
• releasing the therapeutic agent 




• The overexpression of HER2 receptors on the surface of some breast cancer cells provides a 
unique platform for HER2-targeted liposomes 
• in this study   pegylated liposomes + monoclonal antibody Trastuzumab (TRA-
liposomes) was synthesized
• the effect of applying LFUS to stimulate drug release 
• in vitro results showed this method is a safe and effective technique in breast cancer treatment
• future in vivo and clinical work   unlock the full potentials of this promising therapeutic 
technique


